Maroun Justin W, Penza Velia, Weiskittel Taylor M, Schulze Autumn J, Russell Stephen J
Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Medical Scientist Training Program, Mayo Clinic Alix School of Medicine, Rochester, MN, USA.
Mol Ther Oncolytics. 2020 Jun 24;18:236-246. doi: 10.1016/j.omto.2020.06.017. eCollection 2020 Sep 25.
Virus-infected cells release type 1 interferons, which induce an antiviral state in neighboring cells. Naturally occurring viruses are therefore equipped with stealth replication strategies to limit virus sensing and/or with combat strategies to prevent or reverse the antiviral state. Here we show that oncolytic viruses with simple RNA genomes whose spread was suppressed in tumor cells pretreated with interferon were able to replicate efficiently when the cells were coinfected with a poxvirus known to encode a diversity of innate immune combat proteins. the poxvirus was shown to reverse the intratumoral antiviral state, rescuing RNA virus replication in an otherwise restrictive syngeneic mouse tumor model leading to antitumor efficacy. Pairing of complementary oncolytic viruses is a promising strategy to enhance the antitumor activity of this novel class of anticancer drugs.
病毒感染的细胞会释放1型干扰素,从而在邻近细胞中诱导抗病毒状态。因此,天然存在的病毒具备隐蔽复制策略以限制病毒感知和/或具备对抗策略来预防或逆转抗病毒状态。在这里我们表明,具有简单RNA基因组的溶瘤病毒,其在经干扰素预处理的肿瘤细胞中的传播受到抑制,而当这些细胞与一种已知编码多种先天免疫对抗蛋白的痘病毒共感染时,它们能够高效复制。痘病毒被证明可逆转肿瘤内的抗病毒状态,在原本具有限制性的同基因小鼠肿瘤模型中挽救RNA病毒复制,从而产生抗肿瘤疗效。配对互补的溶瘤病毒是增强这类新型抗癌药物抗肿瘤活性的一种有前景的策略。